Pharmafile Logo

Abasaglar

- PMLiVE

The impact of Trump’s victory on pharma and healthcare

Donald Trump’s presidency is unlikely to leave any industry untouched. But how will pharma, biotech and healthcare fare when he takes office?

Sanofi reception

Sanofi wins EU approval for new diabetes combination Suliqua

European Commission licenses the once-daily version of Lantus and Lyxumia

Allergan logo

Allergan plans to file oral uterine fibroid drug in US by year-end

Analysts predict treatment will reach blockbuster sales as phase III trials meet objectives

- PMLiVE

2017 pharma trends: Bon chance!

A US take on the power shift in Washington and what it could mean for the industry

Novartis building

Novartis takes biosimilar delay complaint to Supreme Court

Seeks to overturn US law that requires 180-day launch delay after regulatory approval

Shire Basingstoke

Shire pays record $350m to settle US kickback allegations

Charges centred around diabetic foot ulcer treatment Dermagraft, which it sold in 2014

- PMLiVE

Merck & Co’s Keytruda muscles further ahead of rivals in lung cancer

Granted accelerated review by FDA for use in combination with chemotherapy

- PMLiVE

Pharma ‘getting away with murder’, says Trump

Almost $25bn wiped off big pharma stocks as US President-elect turns attention to drug pricing

- PMLiVE

Kite bags $90m upfront in two Asian deals for lead CAR-T drug

Partners with Daiichi Sankyo and Fosun Pharma to focus in on non-Hodgkin lymphoma

Eli Lilly HQ

Lilly streamlines and culls leadership roles

Merges Europe and emerging markets interests and expands diabetes and oncology

- PMLiVE

Ipsen buys cancer business from stripped down Merrimack

Deal includes pancreatic cancer therapy Onivyde which it hopes will gain first-line approval

- PMLiVE

Amgen wins block on sales of Sanofi/Regeneron’s Praluent

Repatha maintains patent rights but Sanofi and Regeneron set to appeal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links